The effects of losartan on central and peripheral blood pressure;Ovlivnění periferního a centrálního krevního tlaku losartanem

Cor et Vasa

Volumn 52, Issue 3, 2010, Pages 183-186

  Widimský Jr , Jiří ^a   Petrák, Ondřej ^a   Štrauch, Branislav ^a   Vranková, Alice ^a   Zelinka, Tomáš ^a   Dvořáková, Jana ^a   Holaj, Robert ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Arterial hypertension; Blood pressure; Losartan

Indexed keywords

LOSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; HUMAN; PULSE WAVE; SYSTOLIC BLOOD PRESSURE;

EID: 77949779946     PISSN: 00108650     EISSN: None     Source Type: Journal    
DOI: 10.33678/cor.2010.046     Document Type: Article

References (18)

1. Kaplan N. Clinical Hypertension. Philadelphia: Lippincott, Williams and Wilkins, 2006:518.
2. Cheng JW. Aliskiren: renin inhibitor for hypertension management. Clin Ther 2008;30(1):31-46.
3. Widimský J jr, Cifková R, Špinar J, et al. Doporučení diagnostických a léčebných postupu̇ u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008;50:K3-K16.
4. Weber MA. Angiotensin receptor blockers. In: Izzo JL Jr, Sica D, Black HR, eds. Hypertension Primer. Philadelphia: Wolters Kluwer/Lippincott, Williams and Wilkins, 2008:461-464.
5. Boutouyrie P. Tropeano Al, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-15.
6. Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999;33:1111-1117.
7. Amar J, Ruidavets JB, Chamontin B, et al. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001;19:381-387.
8. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664-670.
9. O'Rourke MF, Pauca A, Jiang XJ. Pulse wave analysis. Br J Clin Pharmacol 2001;51:507-522.
10. Conlin PR, Spence JD, Wiliams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13(4 Pt 1):418-426.
11. Fabia MJ, Abdilla N, Oltra R, et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25:1327-1336.
12. Krupička J, Ceypová K, Kristenová P, Hauser T. Bezpečnost dlouhodobého podávání losartanu v běžné klinické praxi: neintervenční Studie NCT-CZ 14/04/LOZ. Vnitř Lék 2008;54:1031-1038.
13. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003;21:821-848.
14. Lindholm LH, Ibsen H, Dahlhöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010.
15. Dahlhöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
16. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
17. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003;21:875-886.
18. Widimský J jr. Léćba hypertenze u metabolického syndromu. Vnitř Lék 2009;55:7-8, 631-635.